STARTUP PROFILE

Axoft

COUNTRY
USA
FOUNDED
2021
CATEGORY
Brain-Computer Interface
Creating ultrasoft, brain‑mimicking implantable interfaces that reduce tissue damage, maintain high electrode density, and enable stable long‑term single‑neuron communication.
Visit website →
Neurofounders Insights
$   Funding   -
Series A
MODALITY
Intracortical
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Multi-indication
TARGET USER
Patients
REGULATORY STAGE
Investigational
Axoft is differentiated by its ultrasoft Fleuron material, which is orders of magnitude more compliant than standard polyimide probes, addressing the chronic tissue-scarring problem that limits long-term signal stability in conventional intracortical implants. With first-in-human cases completed in 2025, it has advanced further into clinical translation than most materials-science-focused BCI startups at seed stage.
Mentioned in Market Notes
MOST RECENT COVERAGE
#
8
FDA Supports the BCI Mission
18 August – 1 September 2026

Axoft introduced Fleuron WISE, a new soft polymer that becomes optically invisible in water by matching its refractive index. The material is built for super-resolution imaging of biological samples, reducing the distortions that normally blur high-resolution views of water-immersed tissue. It extends the Fleuron portfolio that underpins Axoft's brain implants, where the same brain-soft material improves biocompatibility and signal stability. WISE is commercially available now. Axoft will present results at the Materials Research Society meeting in December.

Articles featuring
Axoft